Welcome to AstraZeneca United States

能搜外网浏览器安卓


能搜外网浏览器安卓


能搜外网浏览器安卓

Researching antibodies to target COVID-19

AstraZeneca is joining forces with government and academia with the aim of discovering novel coronavirus-neutralising antibodies. Harnessing internal expertise and via new collaborations, the aim is to identify monoclonal antibodies that have the potential to recognise, bind to and neutralise the SARS-CoV-2 virus, to decrease the impact of COVID-19.

View press release


能搜外网浏览器安卓

Designation based on unprecedented results from the Phase III ADAURA trial where TAGRISSO reduced the risk of disease recurrence or death by c. 80%

能搜外网浏览器安卓

FARXIGA significantly reduced the worsening of renal function or risk of death in patients with chronic kidney disease with and without type 2 diabetes

能搜外网浏览器安卓

Approval based on Phase III ETHOS trial which showed a statistically significant reduction in the rate of exacerbations compared with dual-combination therapies

能搜外网浏览器安卓


能搜外网浏览器安卓

能搜外网浏览器安卓

能搜外网浏览器安卓

laddervnp下载安卓版

百度贴吧——全球最大的中文社区:百度贴吧——全球最大的中文社区。贴吧的使命是让志同道合的人相聚。不论是大众话题还是小众话题,都能精准地聚集大批同好网友,展示自我风采,结交知音,搭建别具特色的“兴趣主题“互动平台。贴吧目录涵盖游戏、地区、文学、动漫、娱乐明星、生活、体育、电脑数码等方方面面,是全球 ...

Important Discoveries in Asthma